These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 4663633)

  • 1. [Treatment of dysfunctional uterine hemorrhages and amenorrheas using a progestagen-estrogen combination].
    Brehm H; Karsznia R; Prinz W; Schmidt G
    Med Monatsschr; 1972 Dec; 26(12):577-9. PubMed ID: 4663633
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of a synthetic progestagen at low doses].
    Gaudefroy M
    Gynecol Prat; 1966; 17():337-43. PubMed ID: 5987259
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tolerance of the gestagen-estrogen combination Noracyclin in contraception and gynecologic indications].
    Willmes HG
    Med Klin; 1967 Jun; 62(24):951-4. PubMed ID: 5627276
    [No Abstract]   [Full Text] [Related]  

  • 4. A new progestogen-estrogen combination for gynecologic therapy and contraception.
    Linthorst G
    Int J Fertil; 1966; 11(1):35-45. PubMed ID: 5936282
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment with ovariostatic drugs in premenopausal syndromes. Cytological control].
    Subrizi DA; Pieroni G
    Riv Ostet Ginecol; 1966 Jun; 21(6):320-6. PubMed ID: 5963561
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of noracycline administered in menstruation disorders on certain biological functions of the female organism. Effects on the protein metabolism].
    Jabloński K; Giermańska T; Filc-Bauer A
    Pol Tyg Lek; 1970 May; 25(18):635-7. PubMed ID: 5429830
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of noracycline administered in menstruation disorders on various biological functions of the female organism. The secretion of ovarian hormones].
    Jabloński K; Zymek-Giermańska T; Filc-Bauer A
    Pol Tyg Lek; 1971 Apr; 26(14):505-7. PubMed ID: 5581640
    [No Abstract]   [Full Text] [Related]  

  • 8. [Estroprogestinic associations in the preclimacteric syndrome: blood coagulation problems].
    Schubert L; Giarola P; Gibelli A; Iurlaro F
    G Gerontol; 1969 Nov; 17(11):1059-66. PubMed ID: 5397790
    [No Abstract]   [Full Text] [Related]  

  • 9. [Handling of a synthetic progestative in a psychiatric milieu].
    Dubor P; Favre-Tissot M; Guyotat J; Haour P; Simonnet ; Vantheemsche G
    J Med Lyon; 1966 Oct; 47(106):1379-85. PubMed ID: 5928220
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects and side-effects of 2 estrogen-lynesterenol combinations used in hormonal ovulation inhibition].
    Jacobs C; Heinen G; Schmal E
    Med Welt; 1974 Sep; 25(35):1351-3. PubMed ID: 4419263
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experiences with gestagen therapy of various gynecologic diseases].
    György G; László J
    Orv Hetil; 1967 Jun; 108(25):1169-71. PubMed ID: 6077686
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical investigations on the usefulness of Lyndiol for contraceptive and therapeutic purposes].
    Liebhart S; Trebicka-Kwiatkowska B
    Endokrynol Pol; 1966; 17(6):717-28. PubMed ID: 5341992
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hormonal treatment of juvenile menstruation disorders].
    Sas M
    Fortschr Med; 1974 May; 92(15):641-2. PubMed ID: 4829461
    [No Abstract]   [Full Text] [Related]  

  • 14. [Influence of noracycline administered for dysmenorrhea on certain biologic functions of the female organism. Its effect on electrolyte metabolism].
    Jabloński K; Giermańska T; Filc-Bauer A
    Pol Tyg Lek; 1970 Nov; 25(47):1789-92. PubMed ID: 5484511
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of synthetic steroid preparations for hemostasis and normalization of menstrual function in juvenile hemorrhages].
    Kuznetsova MN; Antipina NN; Zagorskaia EA
    Vopr Okhr Materin Det; 1978 Feb; 23(2):77-80. PubMed ID: 347706
    [No Abstract]   [Full Text] [Related]  

  • 16. [On the use of a new synthetic estrogen-progestin combination in the treatment of functional gynecologic disorders].
    Fiorino S; Rossi T; Scio A
    Quad Clin Ostet Ginecol; 1966 May; 21(5):282-310. PubMed ID: 5988967
    [No Abstract]   [Full Text] [Related]  

  • 17. [Emergency treatment of dysfunctional hemorrhage with ovulation inhibitors].
    Wespi HJ; Rehsteiner HP
    Geburtshilfe Frauenheilkd; 1966 Dec; 26(12):1576-84. PubMed ID: 5973352
    [No Abstract]   [Full Text] [Related]  

  • 18. [Management of dysfunctional bleeding as well as hyper- and polymenorrheas using high doses of ovulation inhibitors].
    Soergel W
    Geburtshilfe Frauenheilkd; 1969 Feb; 29(2):159-65. PubMed ID: 5386827
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative cytological and histological studies following the use of an ovulation inhibiting estrogen-gestagen combination (Ovositon)].
    Krause W; Böhm W; Müller W
    Gynaecologia; 1968; 166(5):432-45. PubMed ID: 4179218
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advantage of the use of an estroprogestational drug: 3 mg of chlormadinone acetate + 100 mcg of mestranol in endocrine gynecology].
    Bernard I
    Bord Med; 1970; 3(7):1954-60. PubMed ID: 4195405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.